USA |NASDAQ |USD
Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
---|---|---|---|---|
Nov 7, 2022 | Sep 2022 | $-0.19 | - | $-0.19 |
Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
---|---|---|---|---|
Nov 7, 2022 | Sep 2022 | $91.33M | - | $79.55M |
Amicus Therapeutics's next earnings date is Monday, Nov 7, 2022 for the fiscal quarter ending Sep 2022.
Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
---|---|---|---|---|
Sep 2022 | 10 | $-0.19 | $-0.24 | $-0.13 |
Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
---|---|---|---|---|
Dec 2022 | 11 | $-0.88 | $-1.01 | $-0.67 |
Dec 2023 | 11 | $-0.15 | $-0.37 | $0.05 |
Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
---|---|---|---|---|
Sep 2022 | 5 / 0 | $-0.18 | $-0.18 | $-0.18 |
Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
---|---|---|---|---|
Dec 2022 | 1 / 0 | $-0.80 | $-0.79 | $-0.79 |
Dec 2023 | 4 / 0 | $-0.13 | $-0.12 | $-0.07 |
Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
---|---|---|---|---|
Sep 2022 | 11 | $91.33M | $86.00M | $94.80M |
Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
---|---|---|---|---|
Dec 2022 | 12 | $357.19M | $336.93M | $367.75M |
Dec 2023 | 12 | $491.43M | $441.06M | $565.00M |
Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
---|---|---|---|---|
Aug 3, 2022 | Jun 2022 | $-0.22 | - | - |
May 9, 2022 | Mar 2022 | $-0.25 | $-0.30 | -20.00% |
Feb 24, 2022 | Dec 2021 | $-0.16 | $-0.29 | -81.25% |
Nov 9, 2021 | Sep 2021 | $-0.17 | $-0.19 | -14.46% |
Aug 5, 2021 | Jun 2021 | $-0.21 | $-0.19 | 9.35% |
May 10, 2021 | Mar 2021 | $-0.24 | $-0.25 | -6.25% |
Mar 1, 2021 | Dec 2020 | $-0.22 | $-0.27 | -24.94% |
Nov 5, 2020 | Sep 2020 | $-0.21 | $-0.25 | -19.27% |
Aug 10, 2020 | Jun 2020 | $-0.27 | $-0.20 | 26.85% |
May 7, 2020 | Mar 2020 | $-0.28 | $-0.35 | -23.50% |
Mar 2, 2020 | Dec 2019 | $-0.27 | $-0.35 | -28.11% |
Nov 11, 2019 | Sep 2019 | $-0.32 | $-0.24 | 25.30% |
Aug 8, 2019 | Jun 2019 | $-0.33 | $-0.36 | -10.67% |
May 8, 2019 | Mar 2019 | $-0.29 | $-0.56 | -94.24% |
Feb 28, 2019 | Dec 2018 | $-0.28 | $-0.41 | -47.43% |
Nov 5, 2018 | Sep 2018 | $-0.27 | $-0.84 | -209.62% |
Aug 7, 2018 | Jun 2018 | $-0.33 | $-0.33 | -1.20% |
May 8, 2018 | Mar 2018 | $-0.36 | $-0.28 | 21.46% |
Feb 28, 2018 | Dec 2017 | $-0.31 | $-0.41 | -33.12% |
Nov 8, 2017 | Sep 2017 | $-0.31 | $-0.69 | -122.72% |
Aug 7, 2017 | Jun 2017 | $-0.37 | $-0.34 | 7.15% |
May 9, 2017 | Mar 2017 | $-0.36 | $-0.39 | -9.18% |
Mar 1, 2017 | Dec 2016 | $-0.31 | $-0.41 | -31.54% |
Nov 7, 2016 | Sep 2016 | $-0.30 | $-0.33 | -11.22% |
Aug 9, 2016 | Jun 2016 | $-0.33 | $-0.40 | -21.21% |
May 3, 2016 | Mar 2016 | $-0.35 | $-0.35 | -1.16% |
Feb 26, 2016 | Dec 2015 | $-0.32 | $-0.36 | -11.49% |
Nov 3, 2015 | Sep 2015 | $-0.25 | $-0.32 | -28.00% |
Aug 5, 2015 | Jun 2015 | $-0.24 | $-0.27 | -12.50% |
May 5, 2015 | Mar 2015 | $-0.20 | $-0.25 | -25.00% |
Mar 3, 2015 | Dec 2014 | $-0.18 | $-0.24 | -33.33% |
Nov 6, 2014 | Sep 2014 | $-0.21 | $-0.22 | -4.76% |
Aug 7, 2014 | Jun 2014 | $-0.23 | $-0.22 | 4.35% |
May 5, 2014 | Mar 2014 | $-0.24 | $-0.25 | -4.17% |
Mar 3, 2014 | Dec 2013 | $-0.32 | $-0.18 | 43.75% |
Nov 12, 2013 | Sep 2013 | $-0.34 | $-0.29 | 14.71% |
Aug 7, 2013 | Jun 2013 | $-0.35 | $-0.31 | 11.43% |
May 9, 2013 | Mar 2013 | $-0.33 | $-0.35 | -6.06% |
Mar 12, 2013 | Dec 2012 | $-0.37 | $-0.20 | 45.95% |
Nov 5, 2012 | Sep 2012 | $-0.24 | $-0.34 | -41.67% |
Aug 7, 2012 | Jun 2012 | $-0.23 | $-0.20 | 13.04% |
May 10, 2012 | Mar 2012 | $-0.35 | $-0.35 | - |
Feb 13, 2012 | Dec 2011 | $-0.37 | $-0.25 | 32.43% |
Nov 1, 2011 | Sep 2011 | $-0.33 | $-0.28 | 15.15% |
Aug 8, 2011 | Jun 2011 | $-0.32 | $-0.37 | -15.63% |
May 4, 2011 | Mar 2011 | $-0.35 | $-0.39 | -11.43% |
Feb 14, 2011 | Dec 2010 | $-0.15 | $-0.48 | -220.00% |
Nov 8, 2010 | Sep 2010 | $-0.49 | $-0.56 | -14.29% |
Aug 5, 2010 | Jun 2010 | $-0.53 | $-0.41 | 22.64% |
May 6, 2010 | Mar 2010 | $-0.58 | $-0.54 | 6.90% |
Feb 16, 2010 | Dec 2009 | $-0.59 | $1.45 | 345.76% |
Oct 29, 2009 | Sep 2009 | $-0.68 | $-0.59 | 13.24% |
Aug 5, 2009 | Jun 2009 | $-0.65 | $-0.60 | 7.69% |
May 7, 2009 | Mar 2009 | $-0.64 | $-0.55 | 14.06% |
Feb 5, 2009 | Dec 2008 | $-0.62 | $-0.63 | -1.61% |
Nov 3, 2008 | Sep 2008 | $-0.47 | $-0.36 | 23.40% |
Aug 7, 2008 | Jun 2008 | $-0.51 | $-0.41 | 19.61% |
May 13, 2008 | Mar 2008 | $-0.38 | $-0.34 | 10.53% |
Jan 29, 2008 | Dec 2007 | $-0.40 | $-0.53 | -32.50% |
Oct 31, 2007 | Sep 2007 | $-0.46 | $-0.46 | - |
Aug 7, 2007 | Jun 2007 | $-0.48 | $-1.37 | -185.42% |
Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
---|---|---|---|---|
Feb 24, 2022 | Dec 2021 | $-0.78 | $-0.92 | - |
Mar 1, 2021 | Dec 2020 | $-1.02 | $-1.07 | - |
Mar 2, 2020 | Dec 2019 | $-1.38 | $-1.51 | - |
Feb 28, 2019 | Dec 2018 | $-1.74 | $-1.86 | - |
Feb 28, 2018 | Dec 2017 | $-1.60 | $-1.83 | - |
Mar 1, 2017 | Dec 2016 | - | $-1.49 | - |
Feb 26, 2016 | Dec 2015 | - | $-1.20 | - |
Mar 3, 2015 | Dec 2014 | - | $-0.93 | - |
Mar 3, 2014 | Dec 2013 | - | $-1.13 | - |
Mar 12, 2013 | Dec 2012 | - | $-1.09 | - |
Feb 13, 2012 | Dec 2011 | - | $-1.29 | - |
Feb 14, 2011 | Dec 2010 | - | $-1.99 | - |
Feb 16, 2010 | Dec 2009 | - | $-0.29 | - |
Feb 5, 2009 | Dec 2008 | - | $-1.74 | - |
Jan 29, 2008 | Dec 2007 | - | $-2.36 | - |
Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
---|---|---|---|---|
Aug 3, 2022 | Jun 2022 | $86.61M | - | - |
May 9, 2022 | Mar 2022 | $77.13M | $78.72M | 1.02% |
Feb 24, 2022 | Dec 2021 | $83.28M | $82.15M | 0.99% |
Nov 9, 2021 | Sep 2021 | $80.11M | $79.55M | 0.99% |
Aug 5, 2021 | Jun 2021 | $77.41M | $77.41M | 1.00% |
May 10, 2021 | Mar 2021 | $71.65M | $66.40M | 0.93% |
Mar 1, 2021 | Dec 2020 | $70.06M | $70.57M | 1.01% |
Nov 5, 2020 | Sep 2020 | $65.10M | $67.44M | 1.04% |
Aug 10, 2020 | Jun 2020 | $62.38M | $62.35M | 1.00% |
May 7, 2020 | Mar 2020 | $57.49M | $60.52M | 1.05% |
Mar 2, 2020 | Dec 2019 | $52.33M | $55.29M | 1.06% |
Nov 11, 2019 | Sep 2019 | $47.66M | $48.77M | 1.02% |
Aug 8, 2019 | Jun 2019 | $41.13M | $44.13M | 1.07% |
May 8, 2019 | Mar 2019 | $37.86M | $34.05M | 0.90% |
Feb 28, 2019 | Dec 2018 | $30.21M | $32.64M | 1.08% |
Nov 5, 2018 | Sep 2018 | $23.57M | $20.60M | 0.87% |
Aug 7, 2018 | Jun 2018 | $19.16M | $21.31M | 1.11% |
May 8, 2018 | Mar 2018 | $16.89M | $16.70M | 0.99% |
Feb 28, 2018 | Dec 2017 | $14.00M | $14.73M | 1.05% |
Nov 8, 2017 | Sep 2017 | $9.52M | $10.87M | 1.14% |
Aug 7, 2017 | Jun 2017 | $6.69M | $7.16M | 1.07% |
May 9, 2017 | Mar 2017 | - | $4.17M | - |
Mar 1, 2017 | Dec 2016 | - | $2.83M | - |
Nov 7, 2016 | Sep 2016 | - | $2.13M | - |
Aug 9, 2016 | Jun 2016 | - | $0.00 | - |
May 3, 2016 | Mar 2016 | - | $0.00 | - |
Feb 26, 2016 | Dec 2015 | - | $0.00 | - |
Nov 3, 2015 | Sep 2015 | - | $0.00 | - |
Aug 5, 2015 | Jun 2015 | - | $0.00 | - |
May 5, 2015 | Mar 2015 | - | $0.00 | - |
Mar 3, 2015 | Dec 2014 | - | $931.00K | - |
Nov 6, 2014 | Sep 2014 | - | $293.00K | - |
Aug 7, 2014 | Jun 2014 | - | $475.00K | - |
May 5, 2014 | Mar 2014 | - | $456.00K | - |
Mar 3, 2014 | Dec 2013 | - | $324.00K | - |
Nov 12, 2013 | Sep 2013 | - | $39.00K | - |
Aug 7, 2013 | Jun 2013 | - | $0.00 | - |
May 9, 2013 | Mar 2013 | - | $0.00 | - |
Mar 12, 2013 | Dec 2012 | - | $18.41M | - |
Nov 5, 2012 | Sep 2012 | - | $10.64M | - |
Aug 7, 2012 | Jun 2012 | - | $10.64M | - |
May 10, 2012 | Mar 2012 | - | $7.77M | - |
Feb 13, 2012 | Dec 2011 | - | $5.63M | - |
Nov 1, 2011 | Sep 2011 | - | $5.80M | - |
Aug 8, 2011 | Jun 2011 | - | $4.04M | - |
May 4, 2011 | Mar 2011 | - | $5.97M | - |
Feb 14, 2011 | Dec 2010 | - | $922.00K | - |
Nov 8, 2010 | Sep 2010 | - | $0.00 | - |
Aug 5, 2010 | Jun 2010 | - | $0.00 | - |
May 6, 2010 | Mar 2010 | - | $49.48M | - |
Feb 16, 2010 | Dec 2009 | - | $49.48M | - |
Oct 29, 2009 | Sep 2009 | - | $4.91M | - |
Aug 5, 2009 | Jun 2009 | - | $5.36M | - |
May 7, 2009 | Mar 2009 | - | $4.61M | - |
Feb 5, 2009 | Dec 2008 | - | $4.34M | - |
Nov 3, 2008 | Sep 2008 | - | $3.65M | - |
Aug 7, 2008 | Jun 2008 | - | $3.81M | - |
May 13, 2008 | Mar 2008 | - | $3.16M | - |
Jan 29, 2008 | Dec 2007 | - | $1.78M | - |
Oct 31, 2007 | Sep 2007 | - | $0.00 | - |
Aug 7, 2007 | Jun 2007 | - | $0.00 | - |
Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
---|---|---|---|---|
Feb 24, 2022 | Dec 2021 | $307.10M | $305.51M | -0.52% |
Mar 1, 2021 | Dec 2020 | $259.93M | $260.89M | 0.37% |
Mar 2, 2020 | Dec 2019 | $179.29M | $182.24M | 1.64% |
Feb 28, 2019 | Dec 2018 | $89.67M | $91.25M | 1.76% |
Feb 28, 2018 | Dec 2017 | $36.00M | $36.93M | 2.58% |
Mar 1, 2017 | Dec 2016 | - | $4.96M | - |
Feb 26, 2016 | Dec 2015 | - | $0.00 | - |
Mar 3, 2015 | Dec 2014 | - | $1.22M | - |
Mar 3, 2014 | Dec 2013 | - | $363.00K | - |
Mar 12, 2013 | Dec 2012 | - | $18.41M | - |
Feb 13, 2012 | Dec 2011 | - | $21.43M | - |
Feb 14, 2011 | Dec 2010 | - | $922.00K | - |
Feb 16, 2010 | Dec 2009 | - | $64.36M | - |
Feb 5, 2009 | Dec 2008 | - | $14.97M | - |
Jan 29, 2008 | Dec 2007 | - | $1.78M | - |
FOLD's next earnings date is Monday, Nov 7, 2022 for the fiscal quarter ending Sep 30, 2022.
According to analysts, the average EPS estimation for Amicus Therapeutics's next quarterly earnings is $-0.19, with a low EPS estimation of $-0.24, and a high estimation of $-0.13.
Over the last 1 month, EPS estimates have seen 5 upward revisions and 0 downward. The EPS 1 month trend is $-0.18, the last 2 month trend is $-0.18, and the 3 month trend is $-0.18.
Based on analysts, the average revenue estimation is $91.33M, with a low revenue estimation of $86.00M, and a high estimation of $94.80M.
Amicus Therapeutics's previous earnings date was Aug 3, 2022 for its fiscal quarter ended Jun 30, 2022.
Amicus Therapeutics's previous annual earnings date was Feb 24, 2022 for its fiscal year ended Dec 31, 2021.
FOLD's earnings per share (EPS) was $-0.92, missing the consensus analysts forecast of $-0.78 by 17.95% , and higher than the previous year's EPS (Dec 2020) by -14.02%.
Revenues were $305.51M, worse than the forecast of $307.10M by -0.52%, and up by 17.11% from previous year's revenue.
The company reported a net income of $-250.46M.
Amicus Therapeutics reported a free cash flow of $-206.38M for its fiscal year, compared to $-236.52M a year ago.
The company ended the fiscal year with $440.13M in total debt, an increase of 11.11% compared to the previous year.